These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19220425)

  • 21. [The effect of interleukin-7 and interleukin-15 on the production of Th1 and Th2 cytokines by peripheral blood mononuclear cells from patients with tuberculosis].
    Yang XM; Dong DQ; Li C; Yang YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):403-6. PubMed ID: 17045026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: detection by RT-PCR without in vitro stimulation.
    Monteyne P; Van Laere V; Marichal R; Sindic CJ
    J Neuroimmunol; 1997 Dec; 80(1-2):137-42. PubMed ID: 9413269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum and CSF cytokines and matrix metalloproteinases in spinal tuberculosis.
    Patil T; Garg RK; Jain A; Goel MM; Malhotra HS; Verma R; Singh GP; Sharma PK
    Inflamm Res; 2015 Feb; 64(2):97-106. PubMed ID: 25503789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
    Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
    Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variation in PBMC-produced IFN-γ and TNF-α associations with relapse in multiple sclerosis.
    Zhou Y; Taylor B; van der Mei I; Stewart N; Charlesworth J; Blizzard L; Ponsonby AL; Dwyer T; Pittas F; Simpson S
    J Neurol Sci; 2015 Feb; 349(1-2):40-4. PubMed ID: 25575858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
    Navarro JF; Mora C; Gómez M; Muros M; López-Aguilar C; García J
    Nephrol Dial Transplant; 2008 Mar; 23(3):919-26. PubMed ID: 17911088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
    Kivisäkk P; Healy BC; Viglietta V; Quintana FJ; Hootstein MA; Weiner HL; Khoury SJ
    Neurology; 2009 Jun; 72(22):1922-30. PubMed ID: 19487650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
    Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
    Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in cytokine production and surface antigen expression of peripheral blood mononuclear cells after surgery.
    Ono S; Tsujimoto H; Hiraki S; Takahata R; Kinoshita M; Mochizuki H
    Am J Surg; 2005 Sep; 190(3):439-44. PubMed ID: 16105533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.